Results per Page:
Breast Cancer Research Foundation to fund seven Cancer Consortium researchers
BCRF awards $2.6M in grants to Fred Hutch/University of Washington/Seattle Children’s Cancer Consortium researchers
$600,000 in awards against ovarian cancer for Fred Hutch and UW researchers
Research awarded from the Rivkin Center and Andy Hill CARE fund will dramatically improve outcomes for ovarian cancer patients and the clinicians treating them
New funding drives six breast cancer studies
Scientists from Fred Hutch/University of Washington/Seattle Children’s Cancer Consortium receive $1.7M in grants from Breast Cancer Research Foundation
Research into targeted treatments, better prediction models in breast cancer funded
Breast Cancer Research Foundation continues support for research by Fred Hutch/UW/Seattle Children’s Cancer Consortium physicians and scientists
Early clinical trial highlights cancer vaccines as potential affordable, safe and effective breast cancer treatment
From the Cancer Vaccine Institute, University of Washington, and the Cancer Consortium Breast & Ovary Cancers Program
Un ensayo clínico inicial destaca las vacunas contra el cáncer como posible tratamiento asequible, seguro y eficaz contra el cáncer de mama
Del Cancer Vaccine Institute [Instituto de Vacunas contra el Cáncer], la Universidad de Washington y del Cancer Consortium Breast & Ovary Cancers Program [Programa de Cáncer de Mama y Ovario del Consorcio del Cáncer].
Fred Hutch/UW/Seattle Children’s Cancer Consortium breast cancer researchers receive grants
Breast Cancer Research Foundation supports projects including new imaging tracer, better risk prediction for luminal B subtypes, anti-inflammatory vaccine and more
Breast cancer researchers from Hutch / UW Cancer Consortium gain BCRF funding
New grants will support studies aimed at bettering patient outcomes through diet, exercise, vaccines and more
Breast Cancer Research Foundation funds 8 Fred Hutch/UW Cancer Consortium scientists
Nearly $2M will go toward potential therapies for metastatic disease and better risk reduction through diet and exercise
The hidden function of anti-tumoral drug Motolimod to target immunosuppressive cells
from Dr. Nora Disis, Clinical Research Division
Good News: Normal skin cells keep cancer at bay
Celebrating faculty and staff achievements
6 questions in cancer immunotherapy
From cancer vaccines to engineered T cells, experts weigh in on the big unknowns
New breast cancer vaccine ‘promising but not ready for prime time’
Vaccine potentially could be used in the majority of breast cancer patients
Cancer Immunotherapy Trials Network selects member sites
Center-based initiative announces 27 institutional partners in national research effort to accelerate clinical trials of promising cancer immunotherapies